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RESUMO – Introdução: A doença por coronavírus (COVID-19) está relacionada a vários distúrbios extrapulmonares; entretan-
to, pouco se sabe sobre as características e prevalência das doenças cutâneas. Objetivo: Resumir e avaliar as características e 
prevalência das doenças cutâneas relatadas na literatura em doentes com COVID-19. Métodos: Foi realizada uma busca no 
PubMed, SciELO e ScienceDirect entre 01/01/2020 a 28/09/2020. A população-alvo inclui pacientes com doenças de pele e 
diagnóstico positivo para COVID-19. Todos os estudos observacionais, cartas de pesquisa, relatos de casos/séries foram selecio-
nados. Avaliamos estudos observacionais usando modelos de efeitos aleatórios para calcular a prevalência média ponderada 
e intervalo de confiança (IC) de 95%. Avaliamos os estudos de caso usando o teste do qui-quadrado para variáveis dicotômicas 
e o teste de Mann-Whitney para variáveis contínuas. Resultados: Oitenta e sete pacientes de relatos de casos e seis estudos ob-
servacionais com 363 pacientes foram selecionados. São descritos onze tipos de doenças de pele em pacientes confirmados por 
COVID-19. A prevalência média ponderada de distúrbios cutâneos foi de 9,9% (IC 95%: 3,7-24,1). O exantema maculopapular 
foi o distúrbio mais prevalente (37,5%; IC 95%: 21-57%). A latência foi significativamente menor em pacientes com mais de 60 
anos (p=0,041). Conclusão: Cada manifestação cutânea tem suas particularidades e pode ou não acompanhar outros sinais e 
sintomas. É possível que os idosos tenham doença cutânea relacionada ao COVID-19 precocemente. 
PALAVRAS-CHAVE – COVID-19; Doenças da Pele; Infecções por Coronavírus; Manifestações Cutâneas.
COVID-19 and Cutaneous Disorders: What’s Being 
Reported? A Meta-Analysis from Observational 
Studies and Case Reports    
ABSTRACT – Background: Coronavirus disease (COVID-19) is related to several extrapulmonary disorders; however, little is 
known about the skin disorders characteristics and prevalence. Objetive: Summarize and evaluate the skin disorders’ characteris-
tics and prevalence reported in the literature. Methods: We conducted a search on PubMed, SciELO and ScienceDirect between 
01/01/2020 to 09/28/2020. The target population was patients with skin disorder and a positive diagnosis for COVID-19. All 
observational studies, research letters, case series and case reports were selected. We evaluated observational studies using Ran-
dom-effects models to calculate the weighted mean prevalence and 95% confidence interval (CI). We evaluated the case studies 
using the chi-square test for dichotomous variables and the Mann-Whitney test for continuous variables. Results: Eighty-seven pa-
tients from case reports and six observational studies with 363 patients were selected. Eleven types of skin disorders in COVID-19 
confirmed patients are described. Skin disorder weighted mean prevalence was 9.9% (95% CI: 3.7-24.1). Maculopapular rash was 
the most prevalent disorder (37.5%; 95% CI: 21-57%). Latency was significantly lower in patients over 60 years old (p=0.041). 
Conclusion: Each cutaneous manifestation has its particularities and may or may not accompany other signs and symptoms. It is 
possible for the elderly to have COVID-19- related skin disorders early.  
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INTRODUCTION
The first coronavirus disease (COVID-19) cases, cau-
sed by SARS-CoV-2 infection, occurred in the city of Wuhan, 
China, in December 2019. Since then, rapid viral spread 
has led to a pandemic in a few months.1 There are seve-
ral reports about COVID-19 pulmonary and extrapulmonary 
manifestations and every day more is discovered about the 
pathophysiological mechanisms. In which concerns derma-
tological aspects, several reports associate cutaneous ma-
nifestations with the suspicion of infection, while the reports 
with laboratory confirmed cases are limited. One of the bi-
ggest controversies about these manifestations is about the 
culprit: is it a direct reaction to viral infection or a drug-indu-
ced hypersensitivity?
To date, some review studies have been published with 
the aim of synthesizing dermatological findings in COVID-
19. However, there are no studies that quantify the skin 
disorders prevalence and characteristics. Therefore, the ob-
jective of this meta-analysis is to summarize and evaluate 
the skin disorders characteristics that are being reported in 
patients with a COVID-19 confirmed diagnosis.
METHODS
This meta-analysis was conducted following the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) recommendations. A review protocol was registered 
with the International Prospective Register of Systematic Re-
views (PROSPERO) under identification CRD42020213921. 
The ethical board approval was not necessary because it is a 
literature review study.
Data sources and search strategy
Searches for articles were carried out on PubMed, SciELO 
and ScienceDirect from 01/01/2020 to 09/28/2020. The 
search strategy used was: (“COVID-19” OR “novel coronavi-
rus” OR “SARS-CoV-2”) AND (“skin” OR “dermatologic” OR 
“dermatosis” OR “cutaneous”). The search was done using 
the field tag “[tw]” in each word in PubMed. There was no 
language restriction.
Study Section
All studies found should include the following criteria to 
be considered in this work: (a) Study design: observational 
studies (cross-sectional, cohort and case-control), research 
letters, case report or case series; (b) Participants: labora-
tory-confirmed COVID-19 with cutaneous manifestations; 
(c) variables for observational studies: cutaneous manifes-
tation classification and frequency; (d) variables for case 
report or case series: age, sex, cutaneous manifestation 
and topography. Comments and review articles were ex-
cluded.
Two independent authors (KOR, VVZ) evaluated the ti-
tles and abstracts of all identified articles. Full articles were 
obtained when the titles and abstracts met the eligibility cri-
teria or when they did not provide enough information for 
decision making. Inclusion was carried out after the texts 
had been completely read. Controversial decisions between 
authors were reviewed and resolved in a third author (LML) 
presence.
Data extraction
One author (KOR) extracted the information using two 
standard tables, one for observational studies and the other 
for case reports. These data were evaluated by (LML). The 
extracted data are: (a) Study identification: first author, pu-
blication year, country. (b) study design and participants; (c) 
variables: age, sex, cutaneous manifestation, length, laten-
cy, topography, signs and symptoms, laboratory findings, 
prognosis.
Assessment of risk of bias in included studies and 
risk of publication bias
Two independent authors (KOR, VVZ) evaluated studies 
quality and risk of bias using the National Institutes of Heal-
th Study Quality Assessment Tools for observational designs 
and case reports. (Supplementary Table 1.1 and 1.2)
Data synthesis and statistical analysis
The data generated from observational studies and case 
reports were analyzed in different ways. To assess the case 
reports, in the dichotomous variables, the association infe-
rence was made by the appropriate chi-square test (Pearson 
or Fisher). The continuous variables normality was assessed 
by the Shapiro-Wilk test. Difference inferences between con-
tinuous variables were made using the T test or the Mann-
-Whitney test. These assessments were conducted using the 
IBM SPSS Statistics v22 software.
To assess observational studies, the weighted mean pre-
valence and 95% CI was calculated when there were at least 
three studies for a given dichotomous variable. This evalua-
tion used the Random-effects model with the DerSimonian 
and Laird (DL) method and normalization in logit. The studies 
heterogeneity was measured using the I2 values, which mea-
sure the studies total variation percentage. Heterogeneity is 
considered substantial when I2> 50%. The publication bias 
was subjectively assessed using funnel plot (Supplementary 
Table 2.1). Egger’s test was not used because there were no 
more than 10 studies for each variable. These assessments 
were made using the R language with the metafor 2.4-0 li-
brary. A type I error of 5% was considered for all analyzes.
RESULTS
In the three databases, 551 articles were identified. After 
removing the duplicate articles, the titles and abstract of 418 
articles were evaluated by the eligibility criteria. The exclu-
ded works totaled 333, being classified as irrelevant to the 
theme (n=247), review articles (n=54), perspectives (n=21), 
guidelines (n=8) and sample overlap (n=2). After the scree-
ning, 65 case series and case reports and 19 observational 
studies remained. After reading these works in full, 27 case/
series reports were excluded because they deal with only sus-
pected, but not confirmed, patients with COVID-19. Thirteen 
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observational studies were excluded because they deal with 
a population specific to a disease (n=10) or due to insuffi-
cient information (n=3). Finally, the eligible studies totaled 
38 for case/series reports and 6 for observational studies. 
The case/series reports resulted in 87 individuals and the ob-
servational studies resulted in 363 individuals with confirmed 
COVID-19 and with cutaneous manifestation (Fig. 1).
Demographic
The case/series reports have patients from 22 countries: 
Italy (27.6%), Russia (16.1%), USA (13.8%), France (5.7%), 
Japan (4.6%), Iran (3.4%), Egypt (3.4 %), Romania (3.4%), 
Spain (3.4%), Tunisia (2.3%), Belgium (2.3%), United King-
dom (2.3%), India (1.1%), Morocco (1.1%), Paris (1.1% 
), Saudi Arabia (1.1%), Iraq (1.1%), Brazil (1.1%), Greece 
(1.1%), Paraguay (1.1%), Portugal (1.1%), Wales (1.1%). 
Observational studies have patients from 5 countries: Spain 
(66.4%), Turkey (14.3%), China (14.3%), India (3.6%), Jor-
dan (1.4%) (Fig. 2).
Men frequency was higher in both study designs. In case 
reports and observational studies, men represent 56.3% and 
65.6% of the sample, respectively. In the case reports, the 
median age reported was 54 (32 - 66) years in the general 
sample; 57 (25.5 - 69.5) years in men; 50 (33.5 - 62.5) 
years in women (Fig. 2).
Skin manifestations
Eleven types of skin disorders in COVID-19 confirmed 
patients are described: papulovesicular, maculopapular, 
purpuric, urticarial, erythema multiforme, livedoid, chilblain-
-like, zosteriform, bullous, papulosquamous, erythoderma. 
These disorders frequencies, found in the case reports, are 
described in Table 1. The prevalences estimated by observa-
tional studies are described in Table 2.
In the assessment of case reports, female patients are 
associated with a greater maculopapular rash description 
(p=0.015). Other cutaneous descriptions were not associa-
ted with sex. Cases described with chilblain-like lesions are 
associated with age below 20 years (p=0.002).
Topography
The topography most reported was in the trunk, descri-
bed in 69% of the cases. Generalized involvement accounted 
for 7% of cases. Injuries to the palms or soles are described 
in 9% of cases. There was no sex association with facial, 
trunk, upper or lower extremities lesions. Upper extremity in-
volvement was associated with maculopapular rash reports 
(p=0.015). The purpuric rash reports were associated with 
lower extremity topography (p=0.015). Papulovesicular rash 
reports were associated with trunk topography (p<0.001).
General symptoms
Thirty-one distinct signs and symptoms are described. The 
ten most frequent are shown in table 1. Symptoms frequency 
due skin disorder is shown in Table 3. Chilblain-like reports 
was associated with the non-description of fever (p=0.011). 
Maculopapular rash was associated with the non-description 
of dyspnea (p=0.021). Papulovesicular rash was associated 
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Figure 1 - PRISMA diagram describing the selection process. SciELO, Scientific Eletronic Library Online. 
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with pruritus (p=0.014), fever (p=0.004) and airway symp-
toms (i.e. dyspnea, cough or coryza) (p=0.001) description. 
Other skin disorders were not associated with fever or airway 
symptoms description. Sex was not associated with general 
symptoms.
Duration and latency
The skin disorder duration was quantified in 23 cases. 
The median was 8 (7 - 14) days until remission or hospital 
discharge. There was no association between the disorder 
type and its duration over 5 or 8 days. Latency for the skin 
disorder appearance was reported in 60 cases. The median 
was 4 (1 - 9.5) days (Fig. 2).
Papulovesicular rash was associated with latency less 
than 6 days (p=0.016). Maculopapular rash was associa-
ted with latency greater than or equal to 8 days (p=0.043). 
Other skin disorders were not associated with latency greater 
than or equal to 2, 4, 6 or 8 days. Latency and duration did 
not differ statistically between sexes or ages between 20 and 
40 years. Latency was significantly lower in patients over 60 
years old (p=0.041) (Fig. 3).
For each skin disorder, the mean latency was: 3.65 ± 
3.71 days for papulovesicular rash (n=20); 7.8 ± 7.47 days 
for maculopapular  rash (n=20); 6.17 ± 8.35 days for ur-
ticarial rash (n=6); 10.25 ± 7.50 days for purpuric rash 
(n=4).
Laboratorial findings
Laboratory descriptions were poor in the cases reported. 
Low hemoglobin   values (n=5; 6%), lymphopenia (n=11; 
13%), lymphocytosis (n=0), low platelets (n=8; 9%), high 
C-reactive protein (CRP; n=13; 15%), high d-dimer (n=9; 
10%). Skin disorders were not associated with anemia, 
thrombocytopenia and increased values of C-reactive pro-
tein and d-dimer.
DISCUSSION
The advantage of studying two different study designs, 
observational and case/series reports, is to approach the 
same theme from different perspectives. The prevalence es-
timate was made possible by the observational studies eva-
luation. This is not possible only by evaluating case/series 
reports, as there is no methodological control in this study 
design. However, case/series reports are sufficient to detail 
morbid aspects, allowing intrinsic inferences in each morbi-
dity, dealing with strictly independent cases.
The high heterogeneity found in the prevalence analy-
sis is expected. Immunity and responsiveness to an infec-
tion depends on several factors, such as sociodemographic, 
nutritional, genetic, age and morbid history.2 Cutaneous 
manifestations vary according to individual characteristics, 
however, there are reports of individuals from the same fa-
mily who manifested similar disorders while in isolation at 
Figure 2 - Case/series reports characteristics frequency distribution. (a) age frequency, (b) continental frequency, (c) skin disorder duration until 
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Table 1 - Sex, skin manifestation, symptoms, topography and laboratory markers frequency described in 87 
cases.
N (%) N (%)
Sex Topography
• Male 49 56.3 • Trunk 60 69
• Female 38 43.7 • Lower extremity 44 50.6
Dermatosis • Upper extremity 38 43.7
• Papulovesicular 26 29.9 • Arms 18 20.7
• Maculopapular 25 28.7 • Legs 17 19.5
• Purpuric 10 11.5 • Chest 14 16.1
• Urticarial 8 9.2 • Abdomen 10 11.5
• Livedoid 5 5.7 • Back 9 10.3
• Chilblain-like 5 5.7 • Face 8 9.2
• Erythema multiforme 4 4.6 • Feet 8 9.2
• Zosteriform 4 4.6 • Neck 8 9.2
• Bullous 1 1.1 • Thighs 6 6.9
• Papulosquamous 1 1.1 • Soles 6 6.9
• Erythoderma 1 1.1 • Generalized 6 6.9
Symptoms • Hands 6 6.9
• Fever 66 75.9 • Buttocks 5 5.7
• Cough 46 52.9 • Palms 4 4.6
• Dyspnea 26 29.9 • Hips 4 4.6
• Headache 17 19.5 • Axilla 4 4.6
• Weakness 15 17.2 • Fingers 3 3.4
• Coryza 12 13.8 • Toes 3 3.4
• Othersa 39 44.8 Laboratorial Findings
a: chills, asthenia, confusion, pharyngitis, fatigue, malaise, nausea, nodes, 
irritability, sweating, tachypnea, anorexia, conjunctivitis, vomiting, body pain, 
epistaxis, hemoptysis reported in n<8 each.
• Thrombocytopenia (n=17) 8 47.1
• High C-reactive protein (n=17) 13 75.5
• High D-dimer (n=10) 9 90.0
Figure 3 - Dispersion of age vs latency. Latency reports were representative at ages ranging from 0 to 90 years. There is no tendency for regression. 
Individuals aged ≥ 60 years old reported a median of 2 (-1 – 4), being statistically lower than the median of the others (p=0.041)." 
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home.3 This suggests that the COVID-19 cutaneous presen-
tation may not be a random phenomenon, but a pattern may 
exist. One way to reduce the observations heterogeneity be-
tween studies is to work with specific subgroups. However, 
it was not possible to extract these data from observational 
studies eligible for this work.
The skin disorders pooled mean prevalence in patients 
with COVID-19 positive diagnosis is 9.9% (95% CI: 3.7-24.1). 
Only five skin manifestations had a concomitant presentation 
in at least three observational studies. The most prevalent was 
maculopapular rash (37.5%; 95% CI: 21%-57%). In parallel 
with the evaluation of the case/series reports, the maculopa-
pular rash is one of the most published to date.
The demographic distribution has an aspect of scientific 
bias. To date, the countries that lead the COVID-19 confir-
med cases are USA (7 499 341 cases), India (6 757 131 
cases) and Brazil (4 969 141 cases). However, they are the 
least representative countries in this sample. This may reflect 
a low incentive to conduct research and scientific reports.
The most prevalent skin disorder was maculopapular 
rash (37.5%; 95% CI: 21%-57%). This finding is coherent, 
as this rash is the most common among viral infections or 
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CI 95% I2(%) CI 95%
General overview
All Skin-Manifestations 5 136/3576 9.9 [3.7;24.1] 96.5 [90.0; 99.6]
Male 4 189/363 65.6 [46.9; 80.4] 84.5 [45.6; 99.5]
Female 4 155/363 34.4 [19.6; 53.0] 84.5 [45.6; 99.5]
Types of manifestations
Maculopapular rash 5 146/363 37.5 [21.2; 57.3] 76.8 [37.3;99.1]
Urticarial rash 5 87/363 23 [11.9; 39.8] 83.2 [47.0; 97.8]
Chilblain-like 4 38/363 10 [2.4; 33.3] 87.6 [53.8; 99.2]
Livedoid rash 3 22/363 7.5 [5.0; 11.1] 0 [0; <0.1]
Vesicular rash 4 21/363 6.9 [4.5; 10.2] 0 [0; 96.9]
Table 3 - Topography frequency, stratified by sex and skin disorder, described in 87 cases.  
Topography
Trunk Lower extremity Upper extremity Face
Sex
Male (n=49) 34 (69.4%) 20 (40.8%) 16 (32.7%) 3 (6.1%)
Female (n=38) 24 (63.2%) 22 (57.9%) 20 (52.6%) 3 (7.9%)
Dermatosis
Papulovesicular (n=26) 26 (100%) 5 (19.2%) 4 (15.4%) 0 (0%)
Maculopapular (n=25) 19 (76%) 16 (64%) 16 (64%) 5 (20%)
Purpuric (n=10) 1 (10%) 9 (90%) 2 (20%) 0 (0%)
Urticarial (n=8) 3 (37.5%) 5 (62.5%) 6 (75%) 0 (0%)
Erythema multiforme (n=4) 3 4 4 2 (50%)
Livedoid (n=5) 4 (80%) 2 (40%) 3 (60%) 0 (0%)
Chilblain-like (n=5) 3 (75%) 4 (100%) 4 (100%) 2 (50%)
Zosteriform (n=4) 4 (100%) 0 (0%) 0 (0%) 0 (0%)
Bullous (n=1) 1 (100%) 0 (0%) (0%) 0 (0%)
Papulosquamous (n=1) 1 (100%) 0 (0%) 0 (0%) 0 (0%)
Erythroderma (n=1) 1 (100%) 1 (100%) 1 (100%) 1 (100%)
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drug-induced non-immediate hypersensitivity reaction.4 In 
the case/series reports, there was an association with fema-
les (p=0.015), no description of dyspnea (p=0.021), upper 
limbs topography (p=0.015) and described latency greater 
than 8 days (p=0.026). It was described as a rash with con-
fluent erythematous macules and papules, which acquired 
a pale color under pressure (blanchable). The average age 
was 43.3 ± 28.2 and four cases (16%) reported pruritus. 
Despite being the most frequent rash on upper limbs (42%), 
it was described on the trunk, lower limbs and face in 74%, 
65% and 17% of cases, respectively. It was generalized in 
16% of cases. The description of fever was common during 
the rash manifestation,5 but in some cases the rash manifes-
ted without fever6 or after the end of the feverish period.7 
Many cases did not report rash duration, as some patients 
were discharged before complete remission of the condition. 
The average duration presented in 12 cases is 9.0 ± 4.5 
days. When specified, treatments varied with the use of sys-
temic or topical corticosteroids or/and intravenous or oral 
antihistamines.5,8-10
There is a hypothesis that some skin disorders associated 
with COVID-19 may be a drug-induced reaction. Maculopa-
pular rash is one of the main manifestations of non-immedia-
te hypersensitivity to drugs.11,12 There are some histological 
features that help to identify and guide the etiology. In cases 
of hypersensitivity, maculopapular rash tends to present su-
perficial lymphocytic infiltrate, containing eosinophils and, 
sometimes, neutrophils; basal vasculopathy and little or no 
spread of lymphocytes in the dermal papilla or epidermis.12 
However, some reports present histopathology with dense 
lymphocytic infiltrate in the dermal papilla and perivascular, 
as well as the absence of eosinophils, which is an atypical 
drug-induced reaction finding.8,10 Other reports dismiss this 
hypothesis due to clinical history, since the rash manifested 
itself before any drug use.13 Other reports of skin disorders 
have also ruled out the drug-induced reaction hypothesis.14,15
In four cases, they are described as erythema multiforme-
-like, with a circular maculopapular aspect in the shape of a 
target. Erythema multiforme, in a general context, has less 
than 1% prevalence and is typically more common in women 
in 1.5:1 ratio. Precipitating factor is related to an infection in 
90% of cases.16 In evaluated reports, fever and pain were des-
cribed in two (50%) and one (25%) cases, respectively. Pruritus 
has not been described. The distribution was uniform in upper 
and lower extremity and trunk. Generalized involvement oc-
curred in two (50%) cases. Three (75%) cases are female.
Purpuric rash was described as those that did not acquire 
a pale color under pressure (non-blanchable). It is related 
to inflammation of small vessels in the dermis and blood 
leakage.12 In ten cases, there was an association with lower 
extremities presentation (p=0.015), described in 90% of the 
cases. Six cases reported platelet values, only one (17%) re-
ported thrombocytopenia. Histopathological evaluation in 
three patients without previous comorbidities describes lit-
tle inflammatory infiltrate, fibrin thrombus and vessel wall 
complement deposition.15,17 Some purpuric lesions are more 
frequently related to lower extremities, especially in the ab-
sence of thrombocytopenia. Venous hypertension and blood 
stasis, associated with capillary fragility, can be cofactors for 
this clinical condition.18
Papuloveiscular rash has been described as a varicella-
-like rash, with vesicles forming on a papulo-erythematous 
base, which leads to superficial erosions upon rupture. Pru-
ritus was associated with this rash presentation (p=0.014), 
which is frequent in 38% of cases. No pustules were descri-
bed and the liquid eliminated was described as translucent. 
These cases were also associated with fever (p=0.004) in 
96% of the cases and airway symptoms (p=0.001) in 85% 
of the cases. All cases involved trunk. In most cases, vesicles 
appeared during the fever episode, with an average latency 
of 3.7 days, ranging from -2 to 13 days.19 Histological re-
ports have admitted features consistent with a viral rash.14
Chilblain-like lesions description was associated with age 
under 20 years old (p=0.002). These lesions are described 
as erythematous or violaceous, edematous and painful in 
the acral region. There was no association with description 
of fever (p=0.011). Pain and pruritus were described in 40% 
and 20% of cases, respectively. Male sex represents 80% of 
cases. Kerber et al raises a hypothesis that this condition may 
be a COVID-19 late manifestation. Two cases have positive 
SARS-CoV-2 IgG and negative SARS-CoV-2-IgM values, with 
no recent clinical comorbidities.20,21 During this study eligi-
bility process, some cases of chilblain-like were discarded 
because they did not present a positive COVID-19 labora-
tory diagnosis. Considering the hypothesis of latent manifes-
tation, it is prudent, in the future, to conduct investigations 
about these manifestations in COVID-19 suspected cases.
Urticarias were defined as erythematous plaques or pa-
pules with irregular contours. Female sex represents 62.5% 
of the cases. Fever and pruritus were described in 75% 
and 37.5% of cases, respectively. There was no description 
of pain. Upper extremities were the most affected (75% of 
cases). Management included the use of antihistamines and 
corticosteroids which were associated with a good lesional 
remission.22-24 The average latency was 6.2 ± 8.4 days. Full 
symptoms duration has not been quantified, only reported 
as gradual improvement. In two cases existence of previous 
atopy or allergy clinical history that might justify the lesions 
was denied.22,25
According to the Centers for Disease Control and Preven-
tion (CDC, 2020), fever, cough and dyspnea are the most 
common COVID-19 symptoms.26 Symptoms distribution 
found in the case/series reports are coherent. Fever, cough 
and dyspnea were reported in 76%, 53% and 30% of cases, 
respectively. From the first fever or airway manifestation, the 
cutaneous signs appeared in a median of 4 (1 - 9.5) days. 
Unfortunately, sixty-four (74%) cases were not sufficient to 
report the skin disorder duration. In some cases, hospital dis-
charge was made before complete resolution. In others, cli-
nical remission was quantified (e.g. “in a few days”). There is 
a hypothesis that the use of corticosteroids and antihistami-
nes are sufficient to improve COVID-19 skin manifestations. 




However, due to lack of data related to duration and treat-
ment, it was not possible to stratify the sample and perform 
the appropriate hypothesis test.
The median latency between skin disorder onset and first 
general symptoms (e.g. fever, dyspnea, coryza) was signifi-
cantly lower in patients over 60 years old (p=0.041). The 
immune system natural degeneration by age is a factor that 
reflects changes in innate and adaptive responses, as well as 
susceptibility and manifestation to infectious diseases. Aging 
process, by itself, results in altering the balance of inflamma-
tory and anti-inflammatory mediators by the greater oxida-
tive process and cellular apoptosis. The result is an immune 
remodeling with increased pro-inflammatory mediators pro-
duction.27 It is possible that age increases COVID-19 skin 
disorders susceptibility. The average latency in individuals 
younger (n=45) and older (n=15) than 60 years was 5 (2 - 
10) and 2 (-1 - 4) days, respectively.
This study has several limitations. As most of the observa-
tions were conducted in Europe and Asia, care must be taken 
when generalizing these results to the whole world. Few ob-
servational studies have been included, which considerably 
increases the confidence interval of the results. The case/
series reports have low or very low level of evidence and 
many did not follow the Case Reports Guideline (CARE) me-
thodological rigor. The funnel plots evaluation showed subs-
tantial publication bias (publication bias), represented by the 
asymmetry of the points. We recognize, however, that may be 
some studies, published in local non-indexed journals, were 
not included in this study.
CONCLUSION
In conclusion, skin disorders prevalence in COVID-19 la-
boratory-confirmed patients is around 10%. Each cutaneous 
manifestation presented different peculiarities in the case/
series reports evaluation. Maculopapular rash is the most 
prevalent manifestation and its description is associated with 
upper extremities topography and latency over 8 days. Pur-
puric rash description is associated with lower extremities 
topography. Papulovesicular rash is associated with pruri-
tus, fever and airway symptoms. Chilblain-like lesions are 
associated with age under 20 years and absence of recent 
signs and symptoms. The median overall latency was 8 days. 
Individuals over 60 years of age had a significantly lower 
median latency. Fever, cough and dyspnea are the most des-
cribed signs and symptoms. There are no reports of specific 
skin manifestations. So far, there is no approved COVID-19 
treatment and the infection and skin disorders relationship as 
cause and effect is still unclear.
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